Given the unique products OSX have in their portfolio, it is an attractive proposition for a takeover. However, since the company has not been able to make sizeable/ noteworthy inroads into the medical market, a potential buyer may not bid aggressively. Even if OSX gets an offer 50% higher than the current market price, it would be around 48cents per share. At that price, unfortunately most retail investors will not still break even.
At current levels, I am undecided if I want to average out further!
Acquisition in Sight, page-2
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
